|
(11) | EP 2 054 028 B9 |
| (12) | CORRECTED EUROPEAN PATENT SPECIFICATION |
| Note: Bibliography reflects the latest situation |
|
|
| (54) |
SUBCUTANEOUS IMPLANTS RELEASING AN ACTIVE PRINCIPLE OVER AN EXTENDED PERIOD OF TIME SUBKUTANE IMPLANTATE, DIE ÜBER EINEN LÄNGEREN ZEITRAUM EINEN WIRKSTOFF FREISETZEN IMPLANTS SOUS-CUTANÉS LIBÉRANT UN PRINCIPE ACTIF PENDANT UNE DURÉE ÉTENDUE |
|
|
|||||||||||||||||||||||||||||||
| Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). |
Field of the invention
[0001] The present invention relates to subcutaneous implants obtained by extrusion containing an active ingredient, and a hydrophilic excipient dispersed in a PLGA matrix.
State of the art
[0002] Many active ingredients are rapidly metabolized and eliminated by the human or mammalian organism, therefore requiring frequent administration of the drug with the aim of maintaining an adequate therapeutic concentration.
[0004] Among the numerous implants previously described, the subcutaneous implants described in WO00/33809 represent a net improvement with reference to previous subcutaneous implants containing as the active principle a polypeptide dispersed in a matrix of polylactic-glycolic acid in that they are able to release the aforesaid active principle in 6 months. The subcutaneous implants described in said previous patent differ also in that they present an essentially triphasic and not biphasic release profile as clarified in the following manner: release by pure diffusion, diffusion by release following to swelling and release by polymer degradation.
[0005] This progression therefore allows for an extension of release times. In fact when these implants are introduced into an aqueous medium, the water diffuses through the polymeric matrix reaching the peptide particles closest to the surface and subsequently the inner zones.
[0006] The implant remains substantially unmodified for about 6 weeks and in this period releases approximately 30% of the peptide.
[0007] The duration of this stage of pure diffusion is essentially determined by the level of heterogeneity of the peptide dimensions and the rate is essentially determined by the particle content in the PLGA matrix.
[0008] As the active principle presents heterogeneous dimensions, a sufficient quantity of peptide remains after the first stage of dissolution and can be released in the successive stages mentioned, that is release by diffusion and swelling, or release by disintegration of the polymer.
[0009] Subcutaneous implants including those above described suffer from a drawback essentially caused by the fact that the active ingredient release rate during the three successive phases is partially governed by the concentration of active ingredient within the polymeric matrix (the other factors being the intrinsic solubility and diffusion properties of the active ingredient and the characteristics of the PLGA). On one hand, the amount of active ingredients (dose) to be incorporated into the implant depends on the activity of the product and on the expected dosing interval. However big dimensions implants create problem insofar patients compliance is concerned on the other hand small dimensions subcutaneous implants create problems under industrial feasibility aspects since a very thin or very short implant may be difficult to handle and to package.
[0010] It may therefore happen that implants containing a small amount of very potent active ingredient within a "normal" size (i.e. around 1 mm diameter and 1 cm length) presents a very low active ingredient concentration within the polymeric matrix, thus leading to a poor release profile especially in the first two weeks from the administration, afterwards a marked and abrupt release resulting in an overall shortened period if compared to subcutaneous implants containing higher amounts of the active ingredient.
[0011] Subcutaneous implants (Renu Bhardwaj et al. "In vitro evaluation or poly(D,L-lactide-co-glycolide) polymer-based implants containing the alpha-melanocyte stimulating hormone Melatonan-I", Journal of controlled release, vol.45, no.1, 1997, pages 49-55) containing the active principle Melaton-I in the range from 2 to 10%wt have been described. Specifically such a document discloses the incorporation of sodium chloride or methylcellulose with an increase of the peptide release rate during the secondary phase of the release pattern. However, such implants do not guarantee a three-months release with an more gradual release overall with also an increase release in the first phase.
Summary of the invention
[0012] The Applicant has now unexpectedly found subcutaneous PLGA based implants formulations which overcome the above drawback.
[0013] The present invention therefore relates to subcutaneous implants composed of a PLGA based polymeric matrix containing dispersed therein an active ingredient and a hydrophilic excipient so that the weight ratio:
(Active Ingredient (AI) + Excipient (E))/PLGA is higher than 0.05 and lower than 1, and wherein the active principle is chosen from the class consisting of a peptide, an analgesic-narcotic active ingredient and has a particle size distribution comprised between 1 and 63µm and the hydrophilic excipient is selected from mannitol, sorbitol, trehalose, polyvinylpyrrolidone having an average molecular weight of from 6000 to 10000 Da dispersed in a matrix consisting of PLGA and wherein when the hydrophilic excipient is mannitol it is present in weight ratio with respect to the active ingredient ranging from 2:1 to 5:1.
[0014] In fact the subcutaneous having said weight ratio lower than 0.05 behave like the aforesaid subcutaneous implants containing a low amount of active ingredient in the absence of hydrophilic excipient, namely they exhibit a poor release profile especially in the first two weeks from the administration, afterwards a marked and abrupt release resulting in an overall shortened period if compared to subcutaneous implants containing higher amounts of the active ingredient, whereas the subcutaneous implants having the aforesaid weight ratio equal to or higher than 1, release too quickly the active ingredient.
[0015] On the contrary the implants of the invention result to release the active ingredient therein contained with the typical triphasic profile and the presence of this excipient within the formulation modify the release rates during the three successive phases and also modify the overall release duration.
Description of the figure
[0016]
Figure 1 shows, in ordinates, the active ingredient release (% of the total amount released) versus, in abscissa, time expressed in days after immersion in the aqueous medium of the implants described of Example 1.
Figure 2 shows, in ordinates, the active ingredient release (% of the dose) versus, in abscissa, time expressed in days after immersion of the implants described of Example 2.
Figure 3 shows, in ordinates, the active ingredient release (mg of active ingredient) versus, in abscissa, time expressed in days after immersion of the formulations 2#1 and 2#2.
Figure 4 shows, in ordinates, the active ingredient release (% of the total amount released) versus, in abscissa, time expressed in days after immersion of the implants described of Example 3.
Detailed description of the invention
[0017] The aforesaid weight ratio is preferably comprised between 0.3 and 0.9, more preferably between 0.4 and 0.8.
[0018] The hydrophilic excipient is preferably selected from mannitol, sorbitol, trehalose, polyvinylpyrrolidone having an average molecular weight ranging from 6000 to 10000 Da more preferably 8000 Da.
[0019] The subcutaneous implants of the present invention preferably contain an active principle chosen from the class consisting of: a peptide, an analgesic-narcotic active principle.
[0020] More preferably said peptide is chosen from: avorelin, triptorelin, goserelin and leuprorelin.
[0021] As "drugs with narcotic analgesic activity" preferred are morphine and morphinans, i.e. compounds having a chemical structure and activity similar to that of morphine i.e. µ receptor agonists, but also compounds with morphinic-type activity, in other words also µ receptor agonists but with a different chemical structure such as those belonging to the phenylpiperidine class. (Goodman & Gilman's "The pharmacological basis of therapeutics "Ninth Edition Chapter 23 pages 521-555). As phenylpiperidine µ receptor agonists we cite as preferred at least one active principle chosen from the class consisting of meperidine, fentanyl and relative pharmaceutically acceptable salts, fentanyl congeners, for example sufentanyl, alfentanyl, lofentanyl, carfentanyl, remifentanyl and their pharmaceutically acceptable salts.
[0022] Preferably, when the subcutaneous implants according to the present invention contain a peptide as the active ingredient, they show a heterogeneous particles size distribution more preferably ranging from 1 to 63µm or from 1 to 100 µm. Specifically, when the subcutaneous implants of the invention contain the peptides having the aforesaid heterogeneous particles size dimensions, also the hydrophilic excipient has heterogeneous particles size distribution preferably ranging from 10 to 250 µm.
[0023] When the hydrophilic excipient is mannitol it is preferably present in the subcutaneous implants in weight ratio with respect to the active ingredient in amounts ranging from 2:1 to 5:1 and more preferably in weight ratio of 4:1.
[0024] When the hydrophilic excipient is trehalose or polyvinylpyrrolidone it is preferably present in weight ratio with respect to the active ingredient in amounts ranging from 1:6 to 1:1, more preferably of from 1: 5 to 1:2.
[0025] The PLGA contained in the subcutaneous implants according to the present invention has preferably a weight average molecular weight of from 50000.to 150000 Da and a lactic acid/ glycolic acid ranging from 50/50 to 95/5.
[0026] As PLGA polymeric matrix the subcutaneous implants according to the present invention may contain a sole PLGA or that obtained by grinding an extruded product of a blend of:
■ at least two PLGA having different lactic acid/ glycolic acid molar ratios and different weight average molecular weights,
■ a PLGA and PLA having different weight average molecular weights subject matter of the co-pending application filed in the same day of the instants Patent Application.
[0027] The present invention further relates to
□ the process of preparation of the subcutaneous implants containing a sole PLGA which comprises the following steps:
- a) dry- mixing the active ingredient and the hydrophilic excipient,
- b) dry mixing or wet granulating the mixture obtained in step (a) with PLGA in a suitable solvent
- c) drying the wet granulated mixture coming from step (b) up to a maximum solvent content of from 0.5 to 3%
- d) extruding the dried granulated mixture coming from step (c) or the dry mixture coming from step (b).
□ the process of preparation of the subcutaneous implants according to the present invention containing a PLGA obtained by grinding an extruded product of a blend of:
• - at least two PLGA having different lactic acid/ glycolic acid molar ratios and different weight average molecular weights,
• - a PLGA and PLA having different weight average molecular weights, which comprises the following steps:
- A) Mixing at least two PLGA having different weight average molecular weight and different lactic acid/ glycolic acid molar ratio or PLGA with PLA having different weight average molecular weights,
- B) extruding the powder mixture coming from step (a) and then grinding the extruded PLGA mixture, thereby obtaining granules of the blended extruded PLGA,
- C) dry- mixing the active ingredient and the hydrophilic excipient,
- D) dry mixing or (D') wet granulating in a suitable solvent the mixture obtained in step (B) with PLGA coming from step (C)
- E) drying the wet granulated mixture coming from step (D') up to a maximum solvent content of from 0.5 to 3%
- F) extruding the dried granulated mixture coming from step (E) or the dry mixture coming from step (D).
[0028] We report herewith for illustrative but not limiting purposes an example of preparation of subcutaneous implants according to the present invention.
EXAMPLE 1- preparation of subcutaneous implants containing Avorelin (formulations No. Med 011, Med 012 and Med 013)
[0029] Subcutaneous implants containing ingredients as described in the table below are prepared as described in WO00/33809
| Form. Nr | Avorelin (having particle size distribution ranging from 1 to 63 µm) | PLGA (L/G molar ratio 54/46 -molecular weight 51 kg/mol) | Mannitol (excipient) | Excipient VS Active Ingredient ratio (E/AI) | Active ingredient + Excipient VS PLGA ratio (AI+E/PLGA) |
| 1#1 | 25% w/w | 75% w/w | 0% w/w | NA | 1/3 |
| 1#2 | 5% w/w | 75% w/w | 20% w/w | 4/1 | 1/3 |
| 1#3 | 5% w/w | 95% w/w | 0% w/w | NA | 1/19 |
[0030] Figure 1 shows, in ordinates, the active ingredient release (% of the total amount released) versus, in abscissa, time expressed in days after immersion of the implants described of Example 1.
[0031] It is observed that the typical triphasic release pattern and a 3 months release duration are obtained with 25.0 % w/w loading of active agent (Form. 1#1). On the contrary neither the profile nor the duration is maintained when loading the matrix at 5.0% w/w (Form. 1#3). Finally the triphasic profile and the 3 months duration are recovered when adding 20.0% w/w of mannitol to the 5.0% w/w of active agent (1#2).
[0032] In the case of the low active ingredient loading ((Al+E)/PLGA ratio = 1/19), a very limited number of channels exists within the polymeric matrix. The degradation of the polymeric matrix through autocatalysis is therefore accelerated (this leading to a shorter overall release duration). When adding 20% of a very hydrophilic small molecule (Mannitol), a lot of channels are opened so that the circulation of dissolution buffer within the matrix is sufficient to limit the autocatalysis process and, as a consequence, the release of active ingredient are higher in the first weeks than with subcutaneous implants containing the same amount of active ingredient in the sole PLGA and contemporaneously the matrix resists for longer time to hydrolysis.
EXAMPLE 2- preparation of subcutaneous implants containing Avorelin
[0033] Subcutaneous implants containing ingredients as described in the table below are prepared as described in WO00/33809
| Form. Nr | Avorelin (having particle size distribution ranging from 1 to 63 µm) | PLGA (L/G molar ratio 50/50 -molecular weight 100 kg/mol) | Trehalose (excipient) | Excipient VS Active ingredient ratio (E/AI) | Active ingredient + Excipient VS PLGA ratio (AI+E/PLGA) |
| 2#1 | 29% w/w | 71 % w/w | 0% w/w | NA | ≈ 2/5 |
| 2#2 | 20% w/w | 71 % w/w | 9% w/w | ≈ 1/2 | ≈ 2/5 |
| 2#3 | 20% w/w | 49% w/w | 31 % w/w | 3/2 | ≈ 1/1 |
[0034] A 40 mg implant according to formulation 2#1 contains 11.6 mg of Active ingredient when, according to formulations 2#2 and 2#3, the same implant contains 8 mg of active ingredient.
[0035] Figure 2 shows, in ordinates, the active ingredient release (% of the dose) versus, in abscissa, time expressed in days after immersion of the implants described of Example 2.
[0036] It is observed that both formulations 2#1 and 2#2 present the typical triphasic release pattern and a 3 months long release duration. With a similar (≈ 2/5) AI+E/PLGA ratio, these two formulations operate properly even if it is also noticed in this case that the presence of a small hydrophilic molecule (trehalose) tends to increase the dissolution rate during the first month and to delay the second burst (PLGA degradation driven).
[0037] The dissolution profile from formulation 2#3 is also very informative. In this case, AI+E/PLGA ratio is close to 1/1. This means that half of the matrix is occupied by very hydrophilic molecules. Once dropped into the dissolution medium, such an implant presents a huge number of channels allowing the active ingredient to leave the matrix (through a percolation process).
[0038] Figure 3 shows, in ordinates, the active ingredient release (mg of active ingredient) versus, in abscissa, time expressed in days after immersion of the formulations 2#1 and 2#2.
[0039] It is interesting to notice that formulation 2#1 (containing 11.6 mg of active ingredient per depot) and formulation 2#2 (containing 8.0 mg of active ingredient per depot) release almost the same amount of active ingredient over the entire first month after immersion.
[0040] The use of an excipient is clearly a powerful formulation tool. It is useful to allow for a specific implant to operate properly even with low active ingredient loading but it is also useful to modulate a suboptimal release profile up to exactly reach the target
EXAMPLE 3- preparation of subcutaneous implants containing Fentanyl citrate
[0041] Subcutaneous implants containing ingredients as described in the table below are prepared as described in WO00/33809
| Form. Nr | Fentanyl citrate (having particle size distribution ranging from 1 to 63 µm) | PLGA (L/G molar ratio 75/25 -molecular weight 120 kg/mol) | Excipient | Excipient VS Active ingredient ratio (E/AI) | Active ingredient + Excipient VS PLGA ratio (AI+E/PLGA) |
| 3#1 | 36% w/w | 64% w/w | 0% w/w | NA | ≈ 3/5 |
| 3#2 | 36% w/w | 57% w/w | 7% w/w PVP 8KDa | ≈ 1/5 | ≈¾ |
| 3#3 | 36% w/w | 57% w/w | 7% w/w Mannitol | ≈ 1/5 | ≈¾ |
[0042] Figure 4 shows, in ordinates, the active ingredient release (% of the total amount released) versus, in abscissa, time expressed in days after immersion of the implants described of Example 3.
(Active Ingredient (AI) + Excipient (E))/PLGA is higher than 0.05 and lower than 1 and wherein when the hydrophilic excipient is mannitol it is present in weight ratio with respect to the active ingredient ranging from 2:1 to 5:1.
• at least two PLGA having different lactic acid/ glycholic acid molar ratios and different weight average molecular weights,
• a PLGA and PLA having different weight average molecular weights
(a) dry- mixing the active ingredient and the hydrophilic excipient,
(b) dry mixing or (b') wet granulating the mixture obtained in step (a) with PLGA in a suitable solvent
(c) drying the wet granulated mixture coming from step (b) up to a maximum solvent content of from 0.5 to 3%
(d) extruding the dried granulated mixture coming from step (c) or the dry mixture coming from step (b).
A) Mixing at least two PLGA having different weight average molecular weight and different lactic acid/ glycolic acid molar ratio, or the PLGA with PLA having different weight average molecular weight,
B) extruding the powder mix coming from step (A) and then grinding the extruded PLGA mixture, thereby obtaining granules of the blended extruded PLGA,
C) dry- mixing the active ingredient and the hydrophilic excipient,
D) dry mixing or wet granulating in a suitable solvent the mixture obtained in step (B) with PLGA coming from step (C)
E) drying the wet granulated mixture coming from step (D) up to a maximum solvent content of from 0.5 to 3%
F) extruding the dried granulated mixture coming from step (E) or the dry mixture coming from step (D).
(Wirkstoff (W) + Trägerstoff (T)/PLGA höher als 0,05 und niedriger als 1 ist, und wobei wenn der hydrophile Trägerstoff Mannitol ist, dieser in einem Gewichtsverhältnis vorliegt, welches in Bezug zu dem Wirkstoff im Bereich von 2:1 bis 5:1 liegt.
• mindestens zwei PLGA mit unterschiedlichen molaren Verhältnissen von Milchsäure/Glycolsäure und unterschiedlichen gewichtsdurchschnittlichen Molmassen,
• einem PLGA und PLA mit unterschiedlichen gewichtsdurchschnittlichen Molmassen.
(a) Trockenmischen des Wirkstoffs und des hydrophilen Trägerstoffs;
(b) Trockenmischen oder (b') Feuchtgranulieren der in Schritt (a) erhaltenen Mischung mit PLGA in einem geeigneten Lösungsmittel;
(c) Trocknen der feuchtgranulierten aus Schritt (b) stammenden Mischung bis zu einem maximalen Lösungsmittelgehalt von 0,5 bis 3 %;
(d) Extrudieren der getrockneten granulierten aus Schritt (c) stammenden Mischung oder der aus Schritt (b) stammenden trockenen Mischung.
A) Mischen von mindestens zwei PLGA mit unterschiedlichen gewichtsdurchschnittlichen Molmassen und unterschiedlichem molarem Verhältnis von Milchsäure/Glycolsäure oder von dem PLGA mit PLA mit unterschiedlicher gewichtsdurchschnittlicher Molmasse;
B) Extrudieren der aus Schritt (A) stammenden Pulvermischung und anschließendem Zermahlen der extrudierten PLGA-Mischung, wodurch Granulate des gemischten extrudierten PLGA erhalten werden,
C) Trockenmischen des Wirkstoffs und des hydrophilen Trägerstoffs,
D) Trockenmischen oder Feuchtgranulieren der in Schritt (B) erhaltenen Mischung in einem geeigneten Lösungsmittel mit PLGA aus Schritt (C),
E) Trockenen der feuchtgranulierten aus Schritt (D) stammenden Mischung bis zu einem maximalen Lösungsmittelgehalt von 0,5 bis 3 %,
F) Extrudieren der getrockneten granulierten aus Schritt (E) stammenden Mischung oder der trockenen Mischung aus Schritt (D).
• au moins deux PLGA ayant des rapports molaires d'acide lactique/d'acide glycolique différents et différentes masses moléculaires moyennes en poids,
• un PLGA et un PLA ayant des masses moléculaires moyennes en poids différentes.
(a) mélanger à sec l'ingrédient actif et l'excipient hydrophile,
(b) mélanger à sec ou (b') granuler à l'état humide le mélange obtenu à l'étape (a) avec du PLGA dans un solvant approprié,
(c) sécher le mélange granulé humide provenant de l'étape (b) jusqu'à une teneur en solvant maximum de 0,5 à 3%,
(d) extruder le mélange granulé séché provenant de l'étape (c) ou le mélange sec provenant de l'étape (b).
A) mélanger au moins deux PLGA ayant des masses moléculaires moyennes en poids différentes et un rapport molaire d'acide lactique/d'acide glycolique différent, ou bien le PLGA avec le PLA ayant une masse moléculaire moyenne en poids différente,
B) extruder le mélange de poudre provenant de l'étape (A) et meuler ensuite le mélange PLGA extrudé en obtenant ainsi des granules du PLGA mélangé extrudé,
C) mélanger à sec l'ingrédient actif et l'excipient hydrophile,
D) mélanger à sec ou granuler à l'état humide dans un solvant approprié le mélange obtenu à l'étape (B) avec le PLGA provenant de l'étape (C)
E) sécher le mélange granulé humide provenant de l'étape (D) jusqu'à une teneur maximum en solvant de 0,5 à 3%,
F) extruder le mélange granulé séché provenant de l'étape (E) ou le mélange sec provenant de l'étape (D).
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description
Non-patent literature cited in the description
- RENU BHARDWAJ et al.In vitro evaluation or poly(D,L-lactide-co-glycolide) polymer-based implants containing the alpha-melanocyte stimulating hormone Melatonan-IJournal of controlled release, vol., 1997, vol. 45, 149-55 [0011]
- GOODMANGILMAN'SThe pharmacological basis of therapeuticsvol. 23, 521-555 [0021]